Virus kills breast cancer cells in laboratory

	Tweet

A nondisease-causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to Penn State College of Medicine researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development.

Adeno-associated virus type 2 (AAV2) is a virus that regularly infects humans but causes no disease. Past studies by the same researchers show that it promotes tumor cell death in cervical cancer cells infected with human papillomavirus. Researchers used an unaltered, naturally occurring version of AAV2 on human breast cancer cells.

“Breast cancer is the most prevalent cancer in the world and is the leading cause of cancer-related death in women,” said Samina Alam, Ph.D., research associate in microbiology and immunology. “It is also complex to treat.”

Craig Meyers, Ph.D., professor of microbiology and immunology, said breast cancer is problematic to treat because of its multiple stages.

“Because it has multiple stages, you can’t treat all the women the same. Currently, treatment of breast cancer is dependent on multiple factors such as hormone-dependency, invasiveness and metastases, drug resistance and potential toxicities. Our study shows that AAV2, as a single entity, targets all different grades of breast cancer.”

Cells have multiple ways of dying. If damage occurs in a healthy cell, the cell turns on production and activation of specific proteins that allow the cell to commit suicide. However, in cancer cells these death pathways are often turned off, while the proteins that allow the cell to divide and multiply are stuck in the “on” position.

One way to fight cancer is to find ways to turn on these death pathways, which is what researchers believe is happening with the AAV2 virus. In tissue culture dishes in the laboratory, 100 percent of the cancer cells are destroyed by the virus within seven days, with the majority of the cell death proteins activated on the fifth day. In another study, a fourth breast cancer derived cell line, which is the most aggressive, required three weeks to undergo cell death

“We can see the virus is killing the cancer cells, but how is it doing it?” Alam said. “If we can determine which viral genes are being used, we may be able to introduce those genes into a therapeutic. If we can determine which pathways the virus is triggering, we can then screen new drugs that target those pathways. Or we may simply be able to use the virus itself.”

Research needs to be completed to learn how AAV2 is killing cancer cells and which of its proteins are activating the death pathways.

According to Meyers, the cellular myc gene seems to be involved. While usually associated with cell proliferation, myc is a protein also known to promote cell death. The scientists have observed increased expression of myc close to the time of death of the breast cancer cells in the study. They report their results in a recent issue of Molecular Cancer.

AAV2 does not affect healthy cells. However, if AAV2 were used in humans, the potential exists that the body’s immune system would fight to remove it from the body. Therefore, by learning how AAV2 targets the death pathways, researchers potentially can find ways to treat the cancer without using the actual virus.

In ongoing studies, the Penn State researchers have also shown AAV2 can kill cells derived from prostate cancer, methoselioma, squamous cell carcinoma, and melanoma. A fourth line of breast cancer cells – representing the most aggressive form of the disease – was also studied in a mouse breast tumor model, followed by treatment with AAV2. Preliminary results show the destruction of the tumors in the mice, and researchers will report the findings of those mouse studies soon.

###

Other researchers on this project are Brian S. Bowser and Mohd Israr, Department of Microbiology and Immunology; Michael J. Conway, Section of Infection Diseases, Yale School of Medicine; and Apurva Tandon, Department of Microbiology, Immunology and Pathology, Colorado State University.

The Pennsylvania Department of Health, Breast and Cervical Cancer Initiative supported this research. The researchers have filed for a U.S. patent on this work.

###

Contact: Matthew Solovey

717-531-8606
Penn State

RELATED STORIES:
Web Tool Aims to Improve the Workplace for Breast Cancer Survivors   Estrogen-Lowering Drugs Reduce Mastectomy Rates for Breast Cancer Patients   Five years on breast cancer drug tamoxifen beats two   AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes   Study investigates how age relates to survival outcome in patients with early stage breast cancer   Scientists Identify Gene in Breast Cancer Pathway   Genetic approach provides new insight into trastuzumab resistance in breast cancer   New Test Discovered to Better Predict Breast Cancer Outcomes   Teaching Breast Health Early to Reduce Breast Cancer Mortality in D.C.   Researcher Details Role of Apples in Inhibiting Breast Cancer   Breast cancer is hitting Chinese women earlier   Seven quality guidelines for breast, colorectal cancer care   Dieting May Lower Hormone Levels Tied to Breast Cancer   Roche drugs, chemo destroy 46 percent of breast tumors   Genes, lifestyle pose separate breast cancer risks   Breast Cancer Surgery Preserves Artery for Future Heart Surgery   Hair straightening chemicals not linked to breast cancer risk in African-Americans   Breast cancer risk gene discovery fast tracked by new technology   Scott & White Healthcare pathologist is co-investigator on breast cancer study   New ‘seed’ therapy helps pinpoint breast tumors with more accuracy   Mammograms saved lives of women under 50: study   Molecular Breast Imaging: A Better Way to Spot Tumors in Dense Tissue

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]